(Q38216600)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24882677%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

title

Recent advances in antithrombotic treatment for acute coronary syndromes (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24882677%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24882677%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

author name string

James P Howard

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24882677%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

Sotiris Antoniou

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24882677%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

Andrew Wragg

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24882677%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

language of work or name

English

0 references

publication date

31 May 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24882677%20AND%20SRC:MED&resulttype=core&format=json

Expert Review of Clinical Pharmacology

19 March 2020

number of pages

15

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24882677%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

volume

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24882677%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24882677%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

page(s)

507-521

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24882677%20AND%20SRC:MED&resulttype=core&format=json

Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian multicenter trial.

19 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.923306

Combined cardioprotectant and antithrombotic actions of platelet P2Y12 receptor antagonists in acute coronary syndrome: just what the doctor ordered

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.923306

Frequency of adverse clinical events in the 12 months following successful intracoronary stent placement in patients treated with aspirin and ticlopidine (without warfarin).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.923306

A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.923306

Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.923306

Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting : the clopidogrel aspirin stent international cooperative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.923306

Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.923306

Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.923306

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.923306

Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.923306

Dose comparisons of clopidogrel and aspirin in acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.923306

Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.923306

The case for routine genotyping in dual-antiplatelet therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.923306

Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.923306

Prasugrel versus clopidogrel in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.923306

Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.923306

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.923306

Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.923306

Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocar

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.923306

Excess rates of nonfatal myocardial infarction in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel (preventing clinical events or chasing enzymatic ghosts?).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.923306

Prasugrel versus clopidogrel for acute coronary syndromes without revascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.923306

Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.923306

Intravenous platelet blockade with cangrelor during PCI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.923306

Platelet inhibition with cangrelor in patients undergoing PCI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.923306

Effect of platelet inhibition with cangrelor during PCI on ischemic events

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.923306

The duel between dual antiplatelet therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.923306

Facilitated PCI in patients with ST-elevation myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.923306

Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.923306

ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.923306

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.923306

2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Associati

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.923306

SCH 602539, a protease-activated receptor-1 antagonist, inhibits thrombosis alone and in combination with cangrelor in a Folts model of arterial thrombosis in cynomolgus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.923306

Thrombin-receptor antagonist vorapaxar in acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.923306

Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.923306

Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: the lessons from antagonizing the cellular effects of Thrombin–Acute Coronary Syndromes Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.923306

Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.923306

Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.923306

Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.923306

Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.923306

Randomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention: Arixtra Study in Percutaneous Coronary Intervention: a Randomized Evaluation (ASPIRE) Pilot Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.923306

Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.923306

Bleeding and blood transfusion issues in patients with non-ST-segment elevation acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.923306

Bivalirudin started during emergency transport for primary PCI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.923306

Bivalirudin for patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.923306

Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.923306

Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.923306

New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.923306

Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.923306

Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.923306

Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.923306

RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.923306

Apixaban with antiplatelet therapy after acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.923306

Rivaroxaban in patients with a recent acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.923306

Prehospital Abciximab in ST-Segment Elevation Myocardial Infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.923306

Pretreatment with Prasugrel in Non–ST-Segment Elevation Acute Coronary Syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.923306

Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.923306